NRIX
Nurix Therapeutics, Inc.
Key Financials
Revenue
$84.0M
↑ 54.0%
Net Income
$-264457000
↓ 36.6%
Operating Income
$-285666000
↓ 34.1%
EPS (Diluted)
$-3.05
↓ 5.9%
Shareholders' Equity
$538.7M
↑ 2.2%
Total Assets
$688.1M
↑ 2.8%
Total Liabilities
$149.4M
↑ 4.9%
Cash & Equivalents
$247.0M
↑ 124.5%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | NRIX |
| Company Name | Nurix Therapeutics, Inc. |
| CIK | 1549595 |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1130 |
| State of Incorporation | DE |
| Phone | (415) 660-5320 |